

This is a repository copy of Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/111326/

Version: Supplemental Material

## Article:

Diaz, J., Sternberg, C.N., Mehmud, F. et al. (4 more authors) (2016) Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology, 90 (3). pp. 119-126. ISSN 0030-2414

https://doi.org/10.1159/000443647

This is the peer-reviewed but unedited manuscript version of the following article: Diaz J, Sternberg C, N, Mehmud F, Delea T, E, Latimer N, Pandite L, Motzer R, J, Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology 2016;90:119-126. The final, published version is available at http://www.karger.com/?doi=10.1159/000443647

## Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

## Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



